Literature DB >> 36262318

Solubility Measurements and Correlation of MBQ-167 in Neat and Binary Solvent Mixtures.

Jocelyn M Jiménez Cruz1, Cornelis P Vlaar2, Vilmalí López-Mejías3, Torsten Stelzer1.   

Abstract

MBQ-167 is a novel, small-molecule dual inhibitor of Rac and Cdc42, small GTPases that are involved in cytoskeletal organization, cell cycle progression, and cell migration. In an in vivo mouse model, MBQ-167 has been shown to significantly reduce mammary tumor growth and metastasis and is currently undergoing preclinical studies for the treatment of metastatic cancer. To date, no solubility data have been reported for this compound. For this reason, the present study aims to determine the solubility of this compound in eight neat solvents (acetonitrile, 1-butanol, 2-butanol, ethanol, ethyl acetate, methanol, 1-propanol, and 2-propanol) and two binary solvent mixtures [ethyl acetate (2) + heptane (3) and ethanol (2) + water (3)] between the temperatures of 278.15 and 333.15 K. The results obtained employing the polythermal method show that the solubility of MBQ-167 increases with an increase in temperature in all neat solvents used within this study. Moreover, in the two binary solvent mixtures, the solubility of this compound increases with increasing temperature and decreases with an increasing mass fraction of the antisolvent (heptane or water). The experimental solubility data were correlated using the modified Apelblat and λh model equations. The predicted solubility data acquired from the Apelblat and λh model equations correlate well with the experimental solubility data as indicated by the low ARD % (≤1.8304 and ≤6.5366, respectively). No solvent-mediated polymorphic phase transitions were observed while performing the solubility studies, and no other solid forms were detected after the recrystallization in the solvents and solvent mixtures. The solubility data determined here can offer pathways to develop pharmaceutical crystallization processes that can further the translation of MBQ-167 into a clinical setting.

Entities:  

Year:  2020        PMID: 36262318      PMCID: PMC9578765          DOI: 10.1021/acs.jced.0c00908

Source DB:  PubMed          Journal:  J Chem Eng Data        ISSN: 0021-9568            Impact factor:   3.119


  6 in total

Review 1.  Targeting Rac and Cdc42 GTPases in Cancer.

Authors:  María Del Mar Maldonado; Suranganie Dharmawardhane
Journal:  Cancer Res       Date:  2018-06-01       Impact factor: 12.701

2.  Avoiding crystallization of lorazepam during infusion.

Authors:  J Vellema; N G M Hunfeld; H E A Van den Akker; J H ter Horst
Journal:  Eur J Pharm Sci       Date:  2011-10-17       Impact factor: 4.384

3.  Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer.

Authors:  Tessa Humphries-Bickley; Linette Castillo-Pichardo; Eliud Hernandez-O'Farrill; Luis D Borrero-Garcia; Ingrid Forestier-Roman; Yamil Gerena; Manuel Blanco; Michael J Rivera-Robles; José R Rodriguez-Medina; Luis A Cubano; Cornelis P Vlaar; Suranganie Dharmawardhane
Journal:  Mol Cancer Ther       Date:  2017-05       Impact factor: 6.261

Review 4.  Development of EHop-016: a small molecule inhibitor of Rac.

Authors:  Suranganie Dharmawardhane; Eliud Hernandez; Cornelis Vlaar
Journal:  Enzymes       Date:  2013-08-08

5.  Solubility Determination and Correlation of Warfarin Sodium 2‑Propanol Solvate in Pure, Binary, and Ternary Solvent Mixtures.

Authors:  Mery Vet George De la Rosa; Roberto Santiago; Joseph Malavé Romero; Jorge Duconge; Jean-Christophe Monbaliu; Vilmalí López-Mejías; Torsten Stelzer
Journal:  J Chem Eng Data       Date:  2019-04-01       Impact factor: 2.694

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.